Sichuan Huiyu Pharmaceutical Co Ltd (688553) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sichuan Huiyu Pharmaceutical Co Ltd (688553) has a cash flow conversion efficiency ratio of 0.016x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥58.54 Million ≈ $8.57 Million USD) by net assets (CN¥3.72 Billion ≈ $544.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sichuan Huiyu Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Sichuan Huiyu Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Sichuan Huiyu Pharmaceutical Co Ltd for a breakdown of total debt and financial obligations.
Sichuan Huiyu Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sichuan Huiyu Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Shenbao Industrial Co Ltd
SHE:000019
|
0.106x |
|
Metropolitan Kentjana Tbk
JK:MKPI
|
0.034x |
|
BLS International Services Limited
NSE:BLS
|
0.211x |
|
Bright Real Estate Group Co Ltd
SHG:600708
|
-0.004x |
|
Superloop Ltd
AU:SLC
|
0.123x |
|
Ambea AB
ST:AMBEA
|
0.417x |
|
Playtika Holding Corp
NASDAQ:PLTK
|
-1.563x |
|
Corbion NV
AS:CRBN
|
0.063x |
Annual Cash Flow Conversion Efficiency for Sichuan Huiyu Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Sichuan Huiyu Pharmaceutical Co Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see 688553 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.97 Billion ≈ $581.43 Million |
CN¥242.96 Million ≈ $35.55 Million |
0.061x | +244.81% |
| 2023-12-31 | CN¥3.77 Billion ≈ $552.32 Million |
CN¥66.93 Million ≈ $9.79 Million |
0.018x | -66.02% |
| 2022-12-31 | CN¥3.72 Billion ≈ $544.07 Million |
CN¥194.06 Million ≈ $28.40 Million |
0.052x | -58.39% |
| 2021-12-31 | CN¥3.56 Billion ≈ $520.72 Million |
CN¥446.36 Million ≈ $65.32 Million |
0.125x | -75.70% |
| 2020-12-31 | CN¥751.48 Million ≈ $109.97 Million |
CN¥387.95 Million ≈ $56.77 Million |
0.516x | -35.33% |
| 2019-12-31 | CN¥408.65 Million ≈ $59.80 Million |
CN¥326.22 Million ≈ $47.74 Million |
0.798x | +193.22% |
| 2018-12-31 | CN¥-150.70 Million ≈ $-22.05 Million |
CN¥129.06 Million ≈ $18.89 Million |
-0.856x | -1305.63% |
| 2017-12-31 | CN¥-185.32 Million ≈ $-27.12 Million |
CN¥-13.16 Million ≈ $-1.93 Million |
0.071x | -- |
About Sichuan Huiyu Pharmaceutical Co Ltd
Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor injection in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levet… Read more